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Abstract

HEPATITIS B VIRUS AND HEPATITIS A VIRUS IN KINGSTON, JAMAICA:
MATERNAL-CHILD IMMUNITY. Jennifer Lee Hirsh and Francis L. Black,
Department of Epidemiology and Public Health, Yale University, School of Medicine,
New Haven, CT.

This study was performed on women and their infants in Kingston, Jamaica to
assess the impact of Hepatitis B Virus and Hepatitis A Virus in this developing country.
Serological assays for disease-related antigens and antibodies were performed for
epidemiological evaluation. Age-specific prevalences as well as persistence of passive
immunity were among the items considered. The prevalence of Hepatitis B Virus
antigenemia in the population studied in Kingston, Jamaica, is comparatively low (0.33
percent) with respect to other geographical regions. Analagous findings include a low
rate of vertical transmission of Hepatitis B surface Antigen (zero percent), and a low
prevalence rate of Antibody to Hepatitis B core in individuals who lack Antibody to
Hepatitis B surface Antigen (1.0 percent). Evidence of maternally-derived, passivelyacquired immunity to Hepatitis B surface Antigen can be demonstrated as persisting in
40 percent of infants at an average of 6.2 months of age. The overall prevalence of
Antibody to Hepatitis A Virus is 74.6 percent, indicating that by child bearing age, at
least 75 percent of the population have been infected. The age-specific distribution may
either reflect accumulated exposure to Hepatitis A Virus, or may reflect increasing
hygienic and socioeconomic standards. Ironically, this may in fact leave the country
subject to more apparent hepatitis than some countries where children have been
infected with Hepatitis A Virus early in life. Antibodies to Hepatitis A Vims in
neonates are maternally-derived, as opposed to having arisen as a response to acute
infection. Early infection in homes where the mothers have been infected does not pose
a special risk. The prevalence of such passively acquired antibodies to Hepatitis A
Vims is high (58.3 percent) and is most likely a result of high initial titers. As a
developing country, Jamaica has been able to exact considerable control over infections
due to both Hepatitis B Vims and Hepatitis A Vims.
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Introduction

Viral hepatitis is an infection which involves the liver, and four types of
etiologic agents have been classified: 1) Hepatitis A Virus (HAV) 2) Hepatitis B Virus
(HBV) 3) non-A non-B Hepatitis agents, and 4) the Delta agent, associated
concommitantly with HBV. The delta agent is implicated only in the presence of HBV,
and as of present, there is no serologic antigenic determinant of non-A non-B Hepatitis.
Therefore, in assessing the role of viral hepatitis in Jamaica, only the impact of
Hepatitis A and Hepatitis B on women and their infants of the Caribbean island of
Jamaica was studied.

Jamaica

The island of Jamaica encompasses an area of 4,244 square miles. Across it are
approximately 2,388,000 inhabitants, 578,000 of whom live in Kingston, the nation's
capital. The literacy rate is 86 percent, and the life expectancy 71 years. The economy
is supported in part by the bauxite industry, but recently the demand for bauxite has
decreased, and tourism has become an increasingly important source of income. Other
export products include coffee, sugar, bananas, and, unofficially, marijuana. The per
capita income is $1300.15
Although the tourist's perception of Jamaica is that of clear, azure waters off of
white sand beaches, the "land of wood and water", as it was called by its first
inhabitants, the Arawak, is not all that simple. Fifty percent of the island's population
is under the age of twenty, and unemployment remains a large problem.15 Various
"settlement" areas exist within Kingston, where houses are made of concrete and
corrugated zinc; "yards" are partitioned by fences made of flattened gasoline cans; and
chickens, goats, and children scamper underfoot. These houses have no running
water, although water is available at centrally located stations within the settlement.
Forty-six percent of the population live in the urban areas, which amount to a mere 5.5
percent of the island's area.15 The influx of previously rural dwellers has strained the
urban public resources. Not all of Kingston, however, is ghetto. The city is home to
the dance, theater, and music of Jamaica. The fruits of the land and the wares of the
people abound in the marketplace. And Kingston is the location of the University
Hospital of the West Indies, which contains major medical facilities as well as the
medical school. It is here that this study was undertaken.
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H^atmaAVims
Hepatitis A Virus (HAV) is a non-enveloped single-stranded RNA virus which
possesses most of the features of a picomavirus, of which enterovirus is a main
subdivision.22 HAV can be inactivated by ultraviolet radiation, exposure to
formaldehyde and chlorine, or by boiling for one minute. It appears that all strains of
the virus are of one serotype and are antigenically indistinguishable. Antibodies to
HAV (Anti-HAV) present early in the disease are of the IgM class; these peak within a
few weeks. During convalescence, the IgG class predominates.41 After acute hepatitis
illness, Anti-HAV protects the individual from becoming reinfected.7 The mode of
transmission of HAV is primarily via the fecal-oral route,51 thus the prevalence of HAV
infection is an index of the adequacy of sanitary practices. Although water-borne or
food- borne epidemics have been noted, spread of the disease is most often due to
person-to-person contact.51 This occurs as the virus is shed in the fecal material of the
infected individual and is transferred to the mouth of another individual, as may occur
in conditions of close contact and/or poor hygiene.24 HAV is transferred from the
gastrointestinal tract to the liver, and there, primary replication ensues. The virus is
passed into feces via the biliary system.46 Humans are the only natural
epidemiologically important host of HAV.41 Distribution of the virus is worldwide,
based on serological data.46-51 The age distribution of those infected is related to the
level of endemicity of HAV and also the status and rate of change of the
socioeconomic, hygienic, and housing conditions of the recent decades.46 Anti-HAV
prevalence has been shown to be related to socioeconomic level, community size, and
overcrowded housing conditions.47 Viral shedding in feces has been demonstrated two
to three weeks prior to the onset of illness, as marked by jaundice, and for 8 to 10 days
afterward.24 In developed countries, improvements in sanitation and socio-economic
conditions have contributed to a decline in the incidence of HAV.7 No conclusive
evidence for a HAV-c airier state exists,19*41 but Anti-HAV serves as a serologic
marker for previous HAV infection.7 In the general United States population, the
prevalence of Anti-HAV increases with increasing age and decreasing socioeconomic
status. In developing countries, HAV infection and the immunity that follows occur
predominantly in childhood.7 In some countries with high HAV prevalence, nearly
100 percent of the individuals become infected and then develop immunity by the age of
ten.24 Perpetuation of HAV is related to population density, level of sanitation and
hygiene, and socioeconomic conditions.46
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Hepatitis B Virus

Hepatitis B Virus (HBV) is a partly-double stranded DNA virus. The virion,
also known as the Dane particle, contains a circular DNA molecule.57 The virion is
comprised of an outer coat and an inner icosahedral nucleocapsid core. Hepatitis B
surface Antigen (HBsAg), originally referred to as Australia antigen, is present in the
outer coat, and is comprised mainly of two major polypeptides.7 Various HBsAg
subdeterminants have been identified. The common group-reactive antigen

is

shared by all HBsAg isolates. Subtype-specific antigens, d or y, w or r, may also be
present The subtype does not affect the clinical course of the disease, but does serve
as a marker for epidemiologic studies.41 Hepatits B core Antigen (HBcAg) is present
on the nucleocapsid core. HBsAg and HBcAg do not cross react. Hepatitis B e
Antigen (HBeAg) is found only in HBsAg-positive serum.
The course of HBV infection can be followed by the antigenic markers that
appear at various times. HBsAg appears first and is detectable for approximately one to
two months after icterus appears. After the clearance of HBsAg, actively acquired
antibodies to HBs (Anti-HBs) can be detected, at which time resolution of the diseases
occurs; however, about 5-15% of infected patients fail to make antibody to HBsAg
during convalescence.41 Anti-HBs continues to persist in most persons after infection
and is thought to be the protective antibody.7 HBsAg has been identified in nearly
every bodily fluid, but the most common route of transmission is percutaneous via
blood. Other non-percutaneous routes include intimate (especially sexual) contact and
perinatal transmission.20-41
Hepatitis B core Antigen (HBcAg) is not usually detected in patients with HBV
infection because the HBcAg is sequestered within the HBsAg coat.7 Antibodies
against HBcAg (Anti-HBc), however, are detectable from approximately one to two
weeks after HBsAg is detected. Anti-HBc is also present weeks to months before AntiHBs can be detected. Occasionally, there is a temporal gap between the time HBsAg is
cleared and the time that Anti-HBs appears. During this time, the only serologic marker
of HBV infection may be Anti-HBc.45 IgG Anti-HBc may remain detectable for many
years after infection27-61 In chronic infection, IgM Anti-HBc titers may indicate the
level of virus activity. On the other hand, low titers of only IgG Anti-HBc without
other serological evidence of HBV infection may indicate previous Hepatitis B
infection.
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Hepatitis B e Antigen (HBeAg) is found in temporal association with HBsAg.
HBeAg also is associated with high levels of viral replication and represents circulating
intact virions, DNA polymerase, and HBV DNA.7 In self-limited HBV infections,
Anti-HBe becomes detectable; this is associated with a lower level of viral infectivity.
In protracted infections, HBeAg may persist, marking replicative infection with
detectable specific DNA polymerase; this is a time of maximal infectivity. In chronic
HBV infection, Anti-HBe is usually detectable whereas HBeAg is not; this disease
state is often non-replicative.

Clinical Course of Acute Hepatitis Infection

Initial prodromal symptoms include anorexia, nausea, vomiting, fatigue,
malaise, arthralgias, myalgias, headache, pharyngitis, cough, and coryza. Fever of
100 -102°F may also occur. Once jaundice sets in, the prodromal symptoms usually
diminish. The prodrome of Hepatitis B is often more insidious than that of Hepatitis
A.41 The liver becomes enlarged and tender, resulting in right upper quadrant pain and
tenderness. Liver function test results show an increase in the serum
aminotransferases, SGOT and SGPT, as well as an elevation in bilirubin. These
elevations tend to be more prolonged in Hepatitis B.41 In the case of extensive
hepatocellular necrosis, the prothrombin time may become elevated, reflecting a defect
in hepatic synthesis of the enzymes of the clotting cascade. Initial neutropenia and
lymphopenia precede a relative lynphocytosis. Complete recovery, both clinically and
with regards to laboratory test values, usually occurs after one to two months after
Hepatitis A and after three to four months in 75 percent of uncomplicated cases of
Hepatitis B.7 Laboratory values may normalize later in the remainder. Acute Hepatitis
A is generally a self-limited disease, with fulminant hepatic failure rarely occurring 49
However, complicated courses may ensue in those of advanced age or with
underlying medical problems, such as diabetes mellitus or congestive heart failure. The
case fatality rate in Hepatitis A and B is approximately 0.1 percent, but the fatality rate
is one percent in those ill enough to be hospitalized for Hepatitis B 7 Although HAV
has been implicated as the main etiologic agent of fulminant hepatitis in Chilean
children,68 Hepatitis B is responsible for more than fifty percent of fulminant hepatitis,
also known as massive hepatic necrosis, in the general population.7 In this dreaded
complication, patients usually present with encephalopathy and may progress to coma.
The combination of hepatic failure and encephalopathy may be evidenced by rapidly
shrinking liver, elevated prothrombin time and bilirubin levels, ascites, edema,
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confusion, and disorientation. Cerebral edema is common. Fatal sequelae include
brainstem compression, gastrointestinal bleeding, sepsis, respiratory failure,
cardiovascular collapse, and renal failure.7
Approximately 5-10 percent of infected patients may never clear HBsAg from
their circulation,23 and are termed HBsAg carriers. There is an increased incidence of
HBsAg carriers after HBV infection in neonates, homosexual males, and the
immunocompromised individual.41 HBsAg-positive individuals may 1) be
asymptomatic 2) have low-grade chronic persistent hepatitis, or 3) have chronic active
hepatitis. HBsAg-carriers also have an increased incidence of cirrhosis and
hepatocellular carcinoma (HCC). Evidence for this includes both correlation between
geographic distribution of HCC and HBsAg, as well as increased frequency of
detection of HBsAg in individuals with HCC.58 In the United States and Western
Europe, hepatocellular carcinoma comprises only 2 to 2.5 percent of malignant tumors
discovered at autopsy, yet in parts of Africa and Asia, it may comprise 20 to 40 percent
of malignancies.58 During the course of HBV infection, the viral genome becomes
integrated into that of the host. Clones of these hepatocytes are the basis of malignant
transformation.55 The number of persistent carriers in the world, as estimated by
seroepidemiological surveys, is now more than 200 million.23 HCC is a fatal disease,
and most patients die within three to six months of gastrointestinal hemorrhage, hepatic
failure, or cachexia.7 Delta hepatitis virus superimposed on chronic Hepatitis B can
worsen the severity of the latter, even to the point of development of fulminant
hepatitis. HAY does not appear to progress to chronic liver disease.41

7

Materials and Methods
Maternal serum collection from 304 women was performed at the University
Hospital of the West Indies in Kingston, Jamaica between July 11, 1986 and August
18, 1986. These accounted for approximately 85 percent of all deliveries during that
time period. A few omissions were because of seriously complicated births, and a few
were because the women declined to participate, but most omissions represented
problems getting to the patients while they were in the hospital. The women were
representative of a broad socio-economic spectrum from all parts of the city and
surrounding rural areas; however, they represented a more than usually health-aware
population in that a stipulation for admission was initiation of pre-natal care within six
weeks of gestation. The ages of the mothers ranged from 16 to 44 years, with a mean
of 26.0 years. After written consent was obtained, 10 mL of maternal blood was
obtained by venipuncture. The whole blood was allowed to clot. Blood samples were
then centrifuged at 1000 rpm for 10 minutes. The serum from each sample was
removed with a Pasteur pipette. Serum samples were stored in 5 mL aliquots and kept
frozen in a refrigerator freezing unit for approximately three days, until they could be
placed in a -40° F freezer. Serum samples were kept frozen and were transported on
dry ice from Kingston, Jamaica back to New Haven, Connecticut, where they were
stored in a -40°F freezer.

On one occasion, serum samples were noted to be thawed

between transfer from the best available freezer to the -40° F degree freezer at the
University Hospital of the West Indies.
Concommitant placental cord blood samples were obtained, using a 10 mL
syringe and 19 gauge needle. When placental cord blood was obtained at night, the
blood was refrigerated in a glass VacutainerTM tube

morning, when it was

centrifuged. Centrifugation, serum separation, and storage of placental cord samples
were as per the protocol for the maternal samples.
Between December 1986 and January 1987, blood samples from 222 infants of
mothers in the study were obtained by venipuncture. The 145 infants not bled were
omitted because of a rural address outside the geographic range for home visit (51%),
inability to locate the home (31%), failed venipuncture (12%), refusal of permission
(4%), or death of the infant (2%). The mean age at the time of venipuncture was 186.6
days. (6.2 months)
In July of 1987, the serum samples were assayed for 1) Hepatitis B surface
Antigen (HBsAg) 2) Antibody to Hepatitis B surface Antigen (Anti-HBs) 3) Antibody
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to Hepatitis B core Antigen (Anti-HBc) 4) Antibody to Hepatitis A virus (Anti-HAV)
and 5) IgM Antibody to Hepatitis A virus (IgM Anti-HAV) in the following manner.

Hepatitis B surface Antigen (HBsAg)

All 304 maternal samples were assayed for Hepatitis B surface Antigen. Those
maternal samples that were positive for the antigen had assays performed for the
detection of antigen in matched cord and infant sera, when available. For detection of
Hepatitis B surface Antigen, the Riausure E^M radioimmunoassay from ElectroNucleonics Inc. was used. The test was based on the "sandwich" technique. To each
tube with a glass particle containing Antibody to Hepatitis B surface Antigen (goat), 0.2
mL of patient serum was added. Each set of 90 patient serum samples was run with
three positive and seven negative controls. Incubation for 1 hour was performed in
which 24 cycles of sample agitation and settling on the RiausureTM Auto Processor
occurred. Any Hepatitis B surface Antigen present in the serum being tested would
combine with the Antibody to Hepatitis B surface Antigen (goat). 1.0 mL of 0.01 M
phosphate buffer (sodium salts) and 0.15 M NaCl in double distilled water was added
to each of the tubes. A single cycle of sample washing (60 seconds agitation and 90
seconds settling) was performed and the contents of each tube aspirated, allowing for
3-4 mm above the glass particle. 0.1 mL of 125j labelled antibody to Hepatitis B
surface Antigen was added to each tube. Incubation for 1 hour was performed, in
which 24 cycles of sample agitation and settling occurred. Contents of each tube were
aspirated, allowing for 3-4 mm above the glass particle. Four cycles of sample
washing (60 seconds agitation and 90 seconds settling) with 1.0 mL of 0.01 M
phosphate buffer followed by aspiration were performed. Within 24 hours of
completing the assay, radioactivity of each sample was counted in a Packard Auto
Gamma 5650 gamma scintillation counter for one minute.

Antibody to Hepatitis B surface Antigen (Anti-HBs)

Two-hundred five maternal serum samples, negative for HBsAg, were assayed
for antibody to Hepatitis B surface Antigen, using AUSAB^M radioimmunoassay from
Abbott Laboratories. The samples were selected by criterion of adequate volume of
serum but were otherwise felt to be an accurate representation of the population studied.
Those maternal samples that were positive for the antibody had subsequent assays
performed for the detection of antibody in the infant's serum, when available.
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Seven negative and three positive controls were run with each batch of 90
patient serum samples. One polystyrene bead coated with Hepatitis B surface Antigen
was added to each well of a reaction tray. 200 microliters of serum and positive and
negative controls were added to the respective reaction tray wells. Reaction trays were
tapped to ensure complete distribution of liquid over the polystyrene beads. Reaction
trays were covered and incubation at room temperature for 18 hours was performed.
The contents of the wells were aspirated and each bead was washed in the following
manner. A Pasteur pipette attached to a vacuum source was placed next to the bead and
the liquid was aspirated from each well. 4 mL of double distilled water was added to
the well two times, for a total rinse volume of 8 mL, while simultaneously aspirating
the wash solution. Each bead was released from the pipette vacuum at least once
during the wash cycle to assure even washing of the bead surface.
At this point, any antibody to Hepatitis B surface Antigen that was present in
the patient serum sample, would be bound to the polystyrene bead containing Hepatitis
B surface Antigen. 200 microliters of 125i Hepatitis B surface Antigen was then added
to each reaction well. Reaction wells were tapped to ensure that the radioactively
labelled antigen solution completely surrounded the polystyrene beads. Reaction trays
were covered and incubation for 4 hours at room temperature took place. The liquid
solution from each well was aspirated and each polystyrene bead was again washed in
the manner previously described. The beads were transferred from their reaction tray
wells to assay tubes and were then placed in a Packard Auto Gamma 5650 gamma
scintillation counter. Within 24 hours of completing the assay, radioactivity of each
sample and control was counted for one minute.

Antibody to Hepatitis B core Antigen (Anti-HBc)
Ninety-five maternal serum samples, negative for Anti-HBs, were assayed for
the detection of antibody to Hepatitis B core Antigen. These 95 samples were
randomly selected except for the one sample known to be HBs-Antigen-positive. The
decision not to assay the rest of the samples was based on the results of the first 95,
that showed no other Anti-HBc-positivity except in the HBsAg-positive sample. Thus
it was unlikely that HBsAg had been cleared, but Anti-HBs had not yet appeared in our
sera. The CORAB^M assay from Abbott Laboratories was employed. This assay is
based on the principle of competitive inhibition, in which non-radioactive antibodies to
Hepatitis B Core from serum samples compete with a constant amount of radioactive
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antibody to Hepatitis B Core for a limited number of binding sites on beads coated with
Hepatitis B core Antigen.
100 microliters of 125j labelled Antibody to Hepatitis B core Antigen was
added to each well of a reaction tray. 100 microliters of patient serum sample or
controls (three negative and two positive controls) were then added. The reaction tray
was tapped vigorously to ensure thorough mixing of reaction components. One bead
containing Hepatitis B core Antigen was then added to each well. The reaction trays
were covered and incubated at room temperature for 20 hours. The liquid contents of
each well were then aspirated and the beads washed three times with 4 mL of double
distilled water for a total rinse volume of 12 mL. The beads were then transferred to
assay tubes and the radioactivity counted in a Packard Auto Gamma 5650 gamma
scintillation counter for one minute. Controls and unknowns were counted together
within 24 hours of completing the assay.

Antibody to Hepatitis A Virus (Anti-HAVl

Two-hundred one maternal samples were assayed for antibody to Hepatitis A.
The samples were selected by criterion of adequate volume of serum, but were
otherwise felt to be an accurate representation of the population studied. Those
maternal samples that were positive for the antibody had assays performed on the
paired infant's serum, when available. The HAVAB^M radioimmunoassay by Abbott
Laboratories was employed. This assay is based on the principle of competitive
inhibition, in which antibodies to Hepatitis A in the patient's serum compete with
radioactively labelled antibodies to Hepatitis A, for Hepatitis A Virus that is coated on a
bead.
10 microliters of patient serum sample or control serum (three negative and two
positive controls) were placed in the wells of the reaction trays. 200 microliters of 125j
antibody to Hepatitis A Virus was added to each well. One Hepatitis A Virus coated
bead was then placed in each well containing a control or serum sample. Each reaction
tray was covered and tapped to remove any trapped air bubbles. Reaction trays were
incubated at room temperature for 18 hours. The covers were then removed from the
trays and the liquid contents of each well were aspirated. Each bead was washed two
times with 4 mL of double distilled water for a total rinse volume of 8 mL. The beads
were then transferred to counting tubes, and within 24 hours, the radioactivity of each
was determined in a Packard Auto Gamma 5650 gamma scintillation counter for one
minute.
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IgM Antibody to Hepatitis A Virus (IgM Anti-HAV)

Forty-five infant samples that were positive for antibody to Hepatitis A Virus
were assayed for IgM specific for Hepatitis A Virus. These infant samples were
selected at random from the 84 Anti-HAV-positive infant samples and were felt to be an
accurate representation of the population. The HAVAB-M^M assay from Abbott
Laboratories was employed. Specimens were diluted 1:200 with 0.15 M normal saline
in glass tubes and vortexed gently to ensure mixing. 10 microliters of positive control
or negative control or diluted specimen was pipetted into each well. 200 microliters of
specimen diluent was added to each well, and trays were tapped to mix contents. One
bead, coated with Antibody to Human IgM, was added to each well. Specimens were
incubated at room temperature for 2 hours. The liquid was aspirated from each well,
and each bead was washed twice with 4.5 mL double distilled water for a total rinse
volume of 9 mL. 200 microliters of Hepatitis A Virus (Human) was added to each well
containing a bead. Specimens were incubated at room temperature for 22 hours.
Liquid was aspirated from each well and again each bead was washed twice with 4.5
mL double distilled water for a total rinse volume of 9.0 mL. 200 microliters AntiHAV 125i Was pipetted into each well with a bead, and specimens were incubated in a
45° C water bath for 4 hours. Liquid was aspirated and each bead washed with 4.5
mL double distilled water for a total rinse volume of 9.0 mL. Beads were transferred to
properly identified counting tubes and immediately placed in a Packard Auto Gamma
5650 gamma scintillation counter. Count rates were determined for one minute.
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Results

Assay for Hepatitis B surface Antigen (HBsAg)

The radioimmunoassay RIAUSURE^M ,Electro-Nucleonics Inc., is based on
the sandwich technique. If HBsAg is present in the serum sample, it will bind to
Antibody to HBsAg (Anti-HBs) coated on the bead placed in each well. In turn,
labelled Antibody to HBsAg (125j Anti-HBs) will bind to the HBsAg already bound to
the beads, forming an antibody-antigen-antibody "sandwich". (See Figure 1) In this
manner, the amount of radioactivity detected will be directly proportional to the HBsAg
in any serum sample. The appropriate cutoff value was determined as outlined in the
RIAUSURE B™ manual. (See Appendix VI) Only one of the 304 maternal samples
tested (0.33%) had a count-per-minute (cpm) value well above that of the cutoff value,
and was therefore considered to be positive for Hepatitis B surface Antigen. The
mother from whom the sample was taken was 23 years old and lived in a rural area
outside of Kingston proper. The matched cord sample had a count-per-minute value
that was just above the cutoff value, and was considered to be weakly positive for
HBsAg. The matched infant sample, taken at 199 days of age, was negative.

Assay for Antibody to Hepatitis B surface Antigen (Anti-HBs)

The radioimmunoassay AUSAB^M, Abbott Laboratories, is also based on die
sandwich technique. Polystyrene beads coated with Hepatitis B surface Antigen
(HBsAg) are exposed to serum samples which may contain antibody to Hepatitis B
surface Antigen (Anti-HBs). Any Anti-HBs present will bind to the HBsAg on the
bead. In turn,

Hepatitis B surface Antigen (125j_HBsAg) is added and

wil bind to any Anti-HBs already bound to the polystyrene bead, forming an antigenantibody-antigen "sandwich". (See Figure 2). In this manner, the amount of
radioactivity present will be directly proportional to the amount of Anti-HBs in each
sample. The appropriate cutoff value was determined as outlined in the AUSAB^M
manual. (See Appendix VII). Thirty-three of the 205 maternal samples (16.1%) had
cpm values greater than the cutoff value and were therefore considered positive for
Anti-HBs. When results were grouped according to maternal age, 4 of 37 (11%) of
16-20 year olds were positive for Anti-HBs; 12 of 73 (16%) of 21-25 year olds; 11 of
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60 (18%) of 26-30 year olds; 5 of 31 (16%) of 31-40 year olds were positive for AntiHBs. (See Table 1) Of these maternal samples that tested positive, twenty of the
matched infant sera were tested. Eight of the 20 (40%) infant samples had values
greater than the cutoff value and were therefore considered positive for Anti-HBs.

Antibody to Hepatitis B core Antigen (Anti-HBcl

The CORABTM assay, Abbott Laboratories, is a competitive
radioimmunoassay. Any Anti-HBc present in serum samples competes with a constant
amount of

Anti-HBc for a limited number of binding sites on beads that

are coated with Hepatitis B core Antigen (HBcAg). In this manner, the amount of
radioactivity detected is inversely proportional to the amount of Anti-HBc in any given
serum sample. The appropriate cutoff value was determined as outlined in the
CORABTM manual. (See Appendix VIII). Only one of the 95 maternal serum
samples had a cpm value that was less than the cutoff value, and was therefore
considered to be positive for Anti-HBc. Of note, this was the same sample that was
positive for HBsAg, suggesting that the subject may have had an acute concurrent
infection.

Antibody to Hepatitis A Virus

The HAVABTM radioimmunoassay, Abbott Laboratories, is a
competitive binding assay in which any Anti-HAV in a serum sample competes with
i^I-labelled Anti-HAV for binding sites on a bead coated with Hepatitis A Virus
(HAV). In this manner, the amount of radioactivity detected will be inversely
proportional to the amount of Anti-HAV in any given serum sample. The appropriate
cutoff value was determined as outlined in the HAVAB^M manual. (See Appendix IX)
One-hundred fifty of the 201 (74.6%) maternal serum samples tested had cpm values
less than or equal to that of the cutoff value and were therefore considered positive for
Anti-HAV. One-hundred forty-four serum samples from infants of mothers positive
for Anti-HAV were tested. Eighty-four of those 144 (58.3%) infant sera samples
tested positive for Anti-HAV.
When results were grouped according to maternal age, 24 of 33 (73%) of 16-20
year-olds were positive for Anti-HAV; 49 of 76 (64%) of 21-25 year-olds; 47 of 63
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(75%) of 26-30 year-olds; 30 of 39 (77%) of 31-40 year-olds were positive for AntiHAV.
(See Table 2).

IgM Antibody to Hepatitis A Virus (IgM Anti-HAV)

The HAVAB-MTM radioimmunoassay, Abbott Laboratories, is based on the
"sandwich" technique. Beads coated with Antibody to Human IgM bind to any
available IgM in a given serum sample. Hepatitis A Virus (HAV) is then added; Only
if the IgM that is already bound to the bead is directed against HAV, will IgM bind
HAV. Next, 125i Anti-HAV is added and can bind to any HAV already bound in
earlier steps. (See Figure 3). In this manner, the amount of radioactivity detected will
be directly proportional to the amount of IgM directed specifically against HAV in any
given serum sample. The appropriate cutoff value was determined as outlined in the
HAVAB-MTM manual. (See Appendix X). Forty-five infant samples that were
previously found positive for Anti-HAV, were tested for IgM antibody directed against
HAV. All (100%) of the forty-five samples were non-reactive (negative) for IgM
against HAV.
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Discussion
Hepatitis B surface Antigen

Maternal Sera Hepatitis B surface Antigen;
The Jamaican sera reveal only one of the 304 (0.33 percent) of maternal
samples as positive for Hepatitis B surface Antigen (HBsAg). The chronic carrier rate
for HBsAg has been estimated as 0.1-0.2 percent in Britain, the United States, and
Scandanavia; 3 percent in Greece and Southern Italy; and 10-15 percent in Africa and
the Far East.55 Other estimates of the HBsAg chronic carrier rate are 0.1-0.5 percent in
Europe, North America, and Australia; 5 percent in Southern and Eastern Europe and
Central and South America; 5-10 percent in the Middle East; and up to 20 percent in
some parts of Africa, Asia, and the Pacific.23 By comparison, the 0.33 percent HBsAg
prevalence in Jamaican sera is relatively low. The persistent carrier state has been
defined as HBs antigenemia for greater than 6 months.41 Therefore, this one Jamaican
sample that is HBsAg positive may either represent acute Hepatitis or chronic Hepatitis
B carriage. Determination would require further serologic marker studies. High titer
IgM Anti-HBc would indicate acute Hepatitis B whereas low titer would indicate
chronic Hepatitis B. IgG Anti-HBc would also indicate chronic Hepatitis B
infection.55 In any event, it appears that the carrier rate of HBsAg in the population
studied in Jamaica is less than or equal to 0.33 percent. In such low HBsAg prevalence
areas, inoculation of blood continues to be a major mode of of spread, such as via
surgical and dental procedures, intravenous drug abuse, tattooing, acupuncture, and
laboratory accidents, as well as communally utilized razors and tooth brushes.41*69
Others at risk of transmission in low incidence areas include patients on hemodialysis,
blood product recipients, residents in institutions for the mentally handicapped,
prisoners, male homosexuals, and the sexually promiscuous.23 These aforementioned
risks are most likely the mode of transmission in Jamaica, where the prevalence of
Hepatitis B Virus antigenemia is low.

Cord and Infant Sera Hepatitis B surface Antigen:
In the Jamaican study, the only umbilical cord sample that was HBsAgpositive, was that matched to the HBsAg-positive maternal sample. The matched infant
sample, taken at 199 days (6.6 months) of age, was HBsAg-negative. There is some
controversy regarding antigenemia in umbilical cord blood. Some researchers believe
that HBsAg can be transmitted across the placenta, but others doubt its true presence

16

and consider it a result of contamination.54 It has also been demonstrated that in
patients routinely screened during pregnancy, levels of maternal Anti-HBs and cord
Anti-HBs are comparable, whereas HBsAg is much less easily detectable in cord blood
as compared to maternal blood.54 It has therefore been postulated that antibody to HBV
crosses the placental barrier more easily than does the antigen itself, thus first allowing
passive immunization of the fetus in early or mid-gestation and then subsequent
prevention of the disease in utero. 54 Other studies to evaluate prevention of perinatal
transmission have considered infants whose cord blood is HBsAg-positive to have had
intra-uterine infection.34 If we are to believe that HBsAg found in cord blood is not
merely a contaminant, then these studies may partially explain why only some of the
infants whose cord blood is HBsAg-positive go on to develop Hepatitis B antigenemia:
passive immunization provides protection against HBV infection after exposure to
maternal HBsAg.
Vertical transmission is defined as the transmission of Hepatitis B Virus from
mother to infant.54 The first observations of "vertical" or "maternal-child" transmission
of HBV were made in 1972, when familial clustering of HBsAg was noted.43 In this
project, they studied a group of sisters, all of whom were HBsAg-positive. Among
them, they had 24 offspring, 20 of whom were HBsAg-positive (83 percent HBsAgpositivity). Then they studied a group of brothers, all of whom were HBsAg-positive.
Among them, they had 7 offspring, only 1 of whom was HBsAg-positive (14 percent
HBsAg-positivity). This indicated that maternal-child transmission was the mode of
infection. Another fact that supported vertical transmission, was that the one HBsAgpositive child of the brothers, was bom to a mother who had Anti-HBs, indicating that
she had been previously infected and could have vertically transmitted the HBV
infection to her child. Within each family, there was only one subtype of HBV.43 It
has been observed that HBsAg-positive cord blood is not a useful criterion for defining
HBV infection in the infant, because infection often could not be confirmed on follow¬
up serological studies of the child,57 as in our case. However, the presence of HBsAg
in the infant's umbilical cord blood has been shown to be a risk factor in the
development of HBsAg-positivity in the infant.56 In Taiwan, it was observed that 76
percent of infants with HBsAg-positive cord bloods became HBsAg-positive, whereas
only 35 percent of infants with HBsAg-negative cord bloods became HBsAg-positive
by two months of age.56 Other related risk factors in the development of infant
antigenemia include titer of HBsAg, as determined by complement fixation, and
HBsAg-positivity in siblings.56 Indeed, HBsAg in cord blood is not the only factor
influencing vertical transmission of HBV: a study on the maternal-child transmission of
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HBsAg in four ethnic groups in Britain revealed similar proportions of HBsAg
positivity in the cord bloods of the various groups, but vertical transmission was
significantly higher in the Chinese.18 Other studies have conclusively demonstrated the
importance of the maternal Hepatitis B e Antigen in vertical transmission of
HBsAg.4’23’42 Eighty-five percent of infants whose mothers were HBeAg-positive
became HBsAg-positive, versus 31 percent of infants whose mothers were HBeAgnegative. The mean length of follow-up time was 12 months for all infants. The
presence of maternal HBeAg has also been correlated with maternal HBsAg titer, as
determined by complement fixation,4 and with HBsAg-positivity in the infant's
siblings,4 a factor previously shown to be a risk factor for the development of HB V
antigenemia in the infant.53 A decreasing pattern of perinatal transmission may be seen
in areas where improved sanitation and a decrease in number of household members
has occurred 42 Among Japanese women, one of the most important factors is the
capability to convert from a HBeAg-positive to a HBeAg-negative state before reaching
reproductive age. Because dietary protein has been considered to be of primary
importance in immunological competence, it has been postulated that increased protein
comsumption may be responsible for the decrease in HBeAg-positivity.42
Hepatitis B Virus is believed to be causally associated with the development of
Hepatocellular Carcinoma (HCC) by the following chain of events: 1) exposure to
HBV leads to 2) induction of the HBsAg-carrier state, leads to 3) chronic hepatitis,
leads to 4) cirrhosis, leads finally to 5) hepatocellular carcinoma.58 Evidence to
support the causal relationship between HBV and HCC include a close correlation in
the geographic distribution of HCC and HBV, particularly with chronic HBsantigenemia.58 Also, HBsAg is detectable with unusually high frequence in HCC
patients.58 Between 60 and 90 percent of all HCC patients have concurrent cirrhosis,
implying that cirrhosis may be an important factor in the development of HCC.58
There is convincing evidence that vertical transmission of HBV occurs much more
frequently in regions of high- incidence HCC than in low-incidence regions.4’54-56
This is related to the frequence of HBeAg-positivity in HBsAg-carriers 4’44 In HCC
high-incidence areas, the patients with HCC are on average much younger than HCC
patients in low-incidence areas. One possible explanation is that exposure to the
etiologic agent occurs earlier in life in the high-incidence areas,58 such as via maternalchild transmission. Age at which primary HBV infection occurs enhances the
probability of becoming a HBsAg-carrier. Ninety-five percent of those infected
perinatally become chronic carriers, versus fewer than 10 percent of those infected as
adults.53 Because the mortality of hepatocellular carcinoma is virtually 100 percent and
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because in certain countries it is the most common cancer in young men, the impact of
HCC is significant, and therefore related factors, such as vertical transmission of the
Hepatitis B Virus, are important.
Vertically acquired HB V infection is usually anicteric and is recognized by the
appearance of HBsAg between 60 and 120 days after birth.41 The mechanism of
infection is uncertain, although it probably involves ingestion or inadvertent inoculation
of maternal blood by the infant during passage through the birth canal.41 The
frequency of vertical transmission of Hepatitis B Virus to infants from HBsAg-carrier
mothers varies throughout different parts of the world. Studies in Denmark and
Thailand have estimated the HBV vertical transmission rate from HBsAg-positive
mothers as zero percent, whereas that in Greece was 6.5 percent, in the United States
was 16.5 percent, and in Taiwan was 40 percent.54 These geographic differences may
be attributed to a number of factors, including maternal HBsAg titer,54 presence of
Anti-HBe,44 and type of early postpartum care and the degree of physical intimacy
between mother and infant during the neonatal period.54 Antigenemia in the infant
usually develops by the time the infant is 6 months of age. One study demonstrated
that 51 of 63 (81 percent) infants bom to HBsAg-positive mothers became HBsAgpositive by 6 months of age.56 In addition, children who develop antigenemia early on
in life, between two and four months, become persistent HBsAg-camers,41 and it is
known that persistent HBsAg-carriers are at greater risk for hepatocellular carcinoma.58
In contrast to this, most children who become HBsAg-positive later in life have been
shown to lose antigenemia within 6 months of becoming HBsAg-posititive 48
Our data show that one Jamaican cord blood sample was HBsAg-positive. It is
possible that the sample represents intra-uterine infection, with passive immunization of
the infant in utero and subsequent prevention of HBV infection. However, the countper-minute rate was just barely above the cutoff value, and a more likely explanation is
contamination of the cord sample with maternal serum. The infant bom to the HBsAgpositive mother had not developed HBV antigenemia by 199 days (6.6 months) of life.
Since maternal-child transmission by HBsAg-positive mothers occurs in 81 percent of
infants by six months of age, the Jamaican infant will most likely not develop HBV
antigenemia. According to previous studies,48 even in the event that antigenemia does
occur in this 6.6 month old infant, it is not likely to persist. It would appear that the
prevalence of Hepatitis B surface Antigen in Jamaica is relatively low, and maternalchild transmission is not a dominant mode of infection.

Antibody to Hepatitis B surface Antigen (Anti-HBs);
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In the Jamaican data, 33 of 205 (16.1 percent) of maternal samples were
positive for Anti-HBs, indicating that infection had occurred in these individuals. The
serologic evidence of current or past infection varies according to geography. The
prevalence of Antibody to Hepatitis B has been estimated at 7-10 percent in the United
States and Western Europe; 20-50 percent in South America, Southeast Europe, and
North Africa; 60-80 percent in Africa and Southeast Asia, and virtually 100 percent in
the Pacific Islands.46 Other estimates of Anti-HBs are 3-5 percent in Switzerland and
Belgium; 11 percent in the United States; 15 percent in Israel; 34 percent in Yugoslavia;
62 percent in Senegal; and 78 percent in Taiwan.60 By comparison, the prevalence of
Anti-HBs in the Jamaican population studied is at the lower end of the prevalence
spectrum. Hygienic conditions and socioeconomic levels have both been shown to be
inversely proportional to the prevalence of HBV infection.46 Relatively high standards
in Jamaica may be partially responsible for the lower Anti-HBs prevalence seen in the
Kingston population.

Age Distribution of Hepatitis B Infection:
The age distribution for Hepatitis B infection depends on the level of endemicity
of the virus in addition to socioeconomic and hygienic standards and cultural factors.46
Exposure to HBV at an early age is related to degree of intrafamial contact,
socioeconomic and hygienic conditions, and medical standards.46 These factors all
influence the percutaneous inoculation rate of infectious blood and secretions 46 The
exact mechanism of intrafamilial transmission has not been defined.24
Studies done in the Pacific Islands show evidence that the prevalence of HBV
markers increases with age, peaking at about 40 years of age.25 In Ethiopia, the
prevalence of Anti-HBs was shown to be higher in those over the age of 15 years than
in the younger age groups.65 Papaevangelou reports that prevalence of serologic
evidence of past or current infection rises with increasing age throughout life with a rate
that depends on the endemicity of HBV infection 46
The age distribution of the Jamaican data indicate a rise in prevalence of AntiHBs with increasing maternal age. (See Figure 4). It appears that a steady prevalence
level is reached by approximately 30 years of age, indicating that most infection occurs
prior to 30 years. Thus, there is no continuous increase in Anti-HBs prevalence
throughout life in this population, signifying a lack of continuous exposure to HBV
over the course of a lifetime. This attests to the relatively high socioeconomic and
hygienic standards of Kingston, which effectively limit the spread of the disease.
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Anti-HBs: Infant Sera
"Passive Immunization" of the fetus occurs as immunoglobulins of the IgG
subclass, antibodies, are transported from the maternal circulation to that of the fetus.
These IgG molecules reflect various infectious agents to which the mother has been
previously exposed. In the newborn infant at time of birth, levels of immunoglobulin
are similar to those of the mother. There is virtually no immunoglobulin of the IgA or
IgM subclass because the fetus is protected from antigenic stimulus in uiero. However,
if infection occurs, the fetus will respond with antibody production, mainly of the IgM
type. Passively transferred IgG has a half-life of 30 to 40 days, and immunoglobulin
concentration decreases with the first few months of life; the lowest levels occur
between two and four months of age.5 This decline is due to both dilution by infant
growth, and catabolic degredation.52 Maternally derived antibodies are considered to
be protective against HBV for the first 6 months of an infant’s life.65
In the Jamaican study, mothers who would be able to transfer Anti-HBs to their
infants would need to be Anti-HBs-positive themselves. In this group of women,
twenty matched infant samples were available for analysis. Eight of the 20 samples
assayed (40 percent) were Anti-HBs-positive at an average ofl87 days (6.2 months) of
age. This duration of maternally acquired immunity to HBV is similar to that of
immunity to measles in Jamaica, as assessed by hemeagglutination-inhibition.14
Measles antibody half-life in these children was found to be only slightly shorter than
that observed in more developed regions.
Given the low HBsAg prevalence rate found in Jamaica, it would seem that the
Anti-HBs seen in infants at 6.2 months of age is antibody that is passively acquired
from the mother, not antibody synthesized by the infant in response to infection.
Therefore, maternally acquired immunity is present in 40 percent of infants at
approximately 6.2 months of age. IgM studies in these children would confirm this but
were not carried out for reason of cost.

Antibody to Hepatitis B core (Anti-HBc)

The Jamaican sera that were Anti-HBs-negative were assayed for Anti-HBc. In
this manner, assessment could be made of any individuals who had cleared HBsAg but
had not yet demonstrated Anti-HBs. Because of the nature of the assay, any class of
Antibody to Hepatitis B core, be it IgG or IgM, would be able to compete with
radioactively labelled Anti-HBc for binding sites to the HBcAg-coated bead. IgM AntiHBc indicates the acutely infected, highly infectious patient.55 Persistent IgM Anti-
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HBc indicates ongoing HBV chronic hepatitis.55 IgG Anti-HBc in the presence of
Anti-HBs signals clinical or subclinical HBV infection in the remote past.55 IgG AntiHBc in the absence of Anti-HBs indicates persistent viral infection.55 The CORAB™
assay was used as an Anti-HBc survey; further classification of immunoglobulin type
could be made if necessary, pending the results of the Anti-HBc survey. The Jamie an
sera demonstrated only one sample that was positive for Anti-HBc. This sample was
from the same individual who was HBsAg-positive. It is thus most likely that the AntiHBc detected was of the IgM class of immunoglobulins and represented an acutely
infected, highly infectious individual. No other Anti-HBc-positive samples were found
in the group of Anti-HBs-negative samples studied, indicating lack of evidence of
persistent HBV infection in the population. This is consistent with earlier results
showing the low prevalence of HBsAg in the population. The very low prevalence of
Anti-HBc in the absence of Anti-HBs, and the low HBsAg prevalence rate, indicate that
persistent HBV infection or HBV-carriage is infrequent in the population studied in
Jamaica.

Antibody to Hepatitis A Virus (Anti-HAV)

Maternal Sera;
One hundred-fifty of the 201 (74.6 percent) samples studied were Anti-HA Vpositive. The prevalence of Anti-HAV varies with geography. Estimates of Anti-HAV
prevalence are 29 percent in Switzerland,60 34 percent in Ethiopia,65 44 percent in the
United States,60 76 percent in Senegal,60 81 percent in Belgium,60 82 percent in
Nigeria,3 87 percent in Spain,9 89 percent in Taiwan,60 95 percent in Israel,60 97
percent in Yugoslavia,60 and 100 percent in Namibia/SouthWest Africa33 and the
Pacific Islands.67 Prevalence of exposure to HAV in various regions of the world is
considered to be a function of hygienic and developmental factors,19 which are of
utmost important in the fecal-oral spread of the disease.60 Such environmental and
socioeconomic conditions, however, are not the only influencing factors. In Belgium,
for instance, standards of living are similar to those in Switzerland and the United
States; the Anti-HAV prevalence, however, was two to four times that of the other two
countries.60 In general, overall prevalence of Anti-HAV in Jamaica is lower than that
of other developing countries and even lower than that of a few developed countries.
This low level of Anti-HAV-positivity reflects the efficacy of the Kingston water and
sewage systems since the primary mode of transmission of the disease if fecal-oral. As
in other studies,8-9>19.26.31.36,67 t^e prevalence of Anti-HAV increased with increasing
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age. (See Figure 5) Three major age-specific prevalence patterns have been described
for Anti-HAV.24 In the first pattern, rapid acquisition of Anti-HAV occurs early in life,
and most individuals become infected by 10 years of age. This pattern is seen in most
developing countries, where the spread of enteric viruses is facilitated by the prevailing
standards of sanitation and hygiene. The second pattern is that of increasing prevalence
of Anti-HAV with increasing age. This pattern occurs in most developed countries and
urban populations and demonstrates a steady decline in the incidence of infection over
the past three or four decades, as a result of improving standards of sanitation and
hygiene. The third age-specific prevalence pattern is relatively rare, in which an
epidemic of HAV occurs and the virus spreads until all susceptible individuals have
contracted the disease. Having exhausted its supply, the virus then dies out. A high
prevalence of Anti-HAV is detected among those individuals alive at the time of the
outbreak; no antibody is detected among those bom subsequent to it.24 The agespecific prevalence pattern seen in Jamaica is that of increasing prevalence of Anti-HAV
with increasing age, the pattern seen in most developing countries that have experienced
recent advances in hygiene and sanitation. This pattern may be interpreted in two
ways. First, the increasing prevalence with increasing age could represent continuous
exposure to HAV throughout the lifetime of the individual. In this manner, there would
be a cumulative effect of Anti-HAV prevalence in the older segments of the population.
This interpretation, however, conflicts with the epidemiological data that show this
prevalence pattern to occur in regions with recent advances in sanitation and hygiene.
Another interpretation of this age-specific prevalence pattern is that the younger
segments of the population have a lower Anti-HAV prevalence because of recent
improvements in hygiene and sanitation. Before these improvements, an almost
universally immune population was achieved at minimal cost by natural HAV
infections.30 Ironically, this situation creates an interesting dilemna. Hepatitis A Virus
infection is commonly asymptomatic or at least relatively mild in young children, but as
the age of infection increases, so does clinical severity.41 As the risk of HAV infection
continues to decline for younger children, a large suseptible population may result,
providing ample opportunity for future epidemics in young adults.30*41 Therefore
although the prevalence patterns of HAV infection reflect improvements in conditions
of hygiene and socioeconomic standards in Jamaica, future epidemics in a nowsusceptible young adult population are possible.

Infant Sera:
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One-hundred forty-four samples were available for analysis from infants whose
mothers were Anti-HAV-positive. Of these, 84 (58.3 percent) were Anti-HAVpositive. The average age at time of serum collection was 188 days (6.3 months).
Although it is known that maternal antibodies protect infants up until 6 to 8 months of
age, not all others studies have documented such a high prevalence rate of passively
acquired Anti-HAV in infants. One study in Taiwan30 estimated the prevalence of
maternally acquired Anti-HAV as 27 percent at less than one year of age. The estimate
for Mexico was 33 percent.36 The frequency of passively acquired antibody against
HAV in Jamaican infants was 58.3 percent. To determine whether these prevalence
rates were true indicators of passive immunity or whether they instead represented
neonatal infection, infant sera that were Anti-HAV-positive were assayed for Anti-HAV
of the IgM subclass. Diagnosis of HAV infection is performed most reliably by
determination of IgM-Anti-HAV.41 If the infant sample were Anti-HAV-positive but
not IgM-Anti-HAV-positive, the antibody against HAV would presumably be of
maternal origin. The assay for IgM-Anti-HAV revealed that none of the Anti-HAVpositive Jamaican infants tested were positive for IgM-Anti-HAV. Therefore the high
prevalence of Anti-HAV seen in the Jamaican study was a reflection of persistent
maternally acquired antibody, not acute HAV infection. A similar phenomenon of low
prevalence Anti-HBs but high prevalence Anti-HAV in neonates has been reported in
Taiwan.31 The differences in neonatal Anti-HBs and Anti-HAV prevalence are most
likely due to a higher titer of maternally derived Anti-HAV.

Conclusions:

In summary, the prevalence of Hepatitis B Virus antigenemia in the population
studied in Kingston, Jamaica, is comparatively low (0.33 percent) with respect to other
geographical regions. Analagous findings include a low rate of vertical transmission of
Hepatitis B surface Antigen (zero percent), and a low prevalence rate of Antibody to
Hepatitis B core in Anti-HBs-negative individuals (1.0 percent). Evidence of
maternally-derived passively-acquired immunity to Hepatitis B surface Antigen can be
demonstrated as persisting in 40 percent of infants at an average of 6.2 months of age.
The overall prevalence of Antibody to Hepatitis A Virus is 74.6 percent, indicating that
by child bearing age, at least 75 percent have been infected. The age-specific
distribution may either reflect accumulated exposure to Hepatitis A Virus, or may reflect
increasing hygienic and socioeconomic standards, which, ironically, may in fact leave
the country subject to more apparent hepatitis than some countries where children are
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infected with HAV early in life. Antibodies to Hepatitis A Virus in neonates are
maternally-derived, as opposed to arising as a response to acute infection. Early
infection in homes where mothers have been infected does not pose a special risk. The
prevalence of such passively acquired antibodies to Hepatitis A Virus is high (58.3
percent) and is most likely a result of high initial titers. As a developing country,
Jamaica has been able to exact considerable control over infections due to both Hepatitis
B Virus and Hepatitis A Virus.
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Table No. 1
Anti-HBs (Maternal)
Age Range
16-20 yrs
21-25 yrs
26-30 yrs
31-40 yrs

Age;Weighted Mean_ No. (+)_N.Q, lasted_%1±)
4
37
11
18.9 yrs
12
23.0 yrs
73
16
28.2 yrs
11
60
18
31
33.8 yrs
5
16

Table No. 2
Anti-HAV (Maternal)
Aee Ranee
16-20 yrs
21-25 yrs
26-30 yrs
31-40 yrs

Aee:Weiehted Mean_No. (+)No. Tested
24
18.7 yrs
33
23.1 yrs
49
76
28.1 yrs
47
63
33.8 yrs
30
39

26

% (+)
73
64
75
77

Figures
Figure 1
125I Anti-HBs

I
HBsAg (serum)

I
Anti-HBs (bead)

Figure 2
125I-HBsAg

I
Anti-HBs (serum)
I
HBsAg (bead)

Figure 3
125I-Anti-HAV
I
HAV

I
IgM against HAV

I
Anti-Human IgM
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Figure 5
Age-Specific Prevalence of Anti-HAV
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Appendix
I. Hepatitis B surface Antigen (HBsAg) Lot Nos.
RIAIJSURE II™, Electro-Nucleonics Laboratories, Inc.
Master Lot No. 1419, 1420, 1421
125I Anti-HBs: 3901417
CPG Tablet: 3906234
Positive Control: 3903081
Negative Control: 3902115
Buffer: 3410002

n. Antibody to Hepatitis B surface Antigen (Anti-HBs) Lot Nos.
AUSAB™, Abbott Laboratories
Maternal Samples
Hepatitis B surface Antigen beads: 02499M103
Positive Control: 01239BW00
Negative Control: 01495BW03
125I Anti-Hbs: 2968M103
Infant Samples
Hepatitis B surface Antigen beads: 03068M303
Positive Control: 02625M302
Negative Control: 03220M303
125I Anti-HBs: 05920M103

HI. Antibody to Hepatitis B core Lot Nos.
CORAB™, Abbott Laboratories
Master Lot No.: 06435M100
Hepatitis B core Ag (rDNA) coated beads: 02387M202
Positive Control: 03968M103
Negative Control: 02506M302
125I Anti-HBc: 05038M203

IV. Antibody to Hepatitis A Lot Nos.
HAVAB™, Abbott Laboratories
Maternal Samples:
Master Lot No.: 06142M100
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Hepatitis A beads: 04881M103
Positive Control: 04376M203
Negative Control: 04377M203
1251 Anti-HAV: 05579M102
Infant Samples:
Master Lot No.: 06769M100
Hepatitis A beads: 04881M103
Positive Control: 04376M203
Negative Control: 04377M203
1251 Anti-HAV: 05991M202

V. IgM Antibody to Hepatitis A Lot Nos.
HAVAB-M™, Abbott Laboratories
Master Lot No.: 22591M100
Positive Control: 18195M302
Negative Control: 18223M203
Ab to Human IgM coated beads: 18206M302
Specimen diluent: 18176M302
HAV: 19922M203
1251 Anti-HAV: 21112M202

VI. Calculation of Cutoff Value for Assay for HBsAg
A. Mean value in counts per minute (cpm) of negative controls calculated by
taking the average of the individual negative control values.
B. Acceptable range for individual values of negative controls is
(0.5-1.5) times the mean. All samples must be re-run if more than one result
is outside this range.
C. Mean value (in cpm) of positive controls is calculated by taking
the average of the individual positive control values.
D. Positive Control Mean divided by Negative Control Mean must be
greater than 5 for test data to be valid.
E. Cutoff Value=[Negative Control Mean (cpm)-Background (cpm)] X2 +
background (cpm).
All specimens which are greater than this value must be
considered reactive for HBsAg.
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VH. Calculation of Cutoff Value for Assay for Anti-HBs.
A. Negative Control Mean (in cpm) is calculated by taking the
average of the individual negative control values.
B. Elimination of one (or no) aberrant values of negative controls
1. Each value must lie within the range of (0.5-1.5) times the
negative control mean.
2. If more than one value lies outside this range, technique
problems should be investigated.
C. Positive Control Mean (in cpm) is calculated by taking the
average of the individual positive control values.
D. Positive Control Mean divided by Negative Control Mean
must be greater than or equal to 15.0 for technique to be
acceptable and data considered valid.
E. Cutoff Value = (Negative Control Mean - Background) X 2.1
+ Background. Samples with gross count rates greater than this value are
considered to be reactive with respect to Anti-HBs.

Vm. Calculation of Cutoff Value for Assay for Anti-HBc
A. Negative Control Mean (in cpm) is calculated by subtracting background
radiation from individual negative control values and then taking the average
of the net values.
B. Elimination of one (or no) aberrant values of negative controls:
1. Each value must lie within the range of (0.5-1.5) times the
negative control mean.
2. If more than one value lies outside this range, technique problems
should be investigated.
3. If one value is outside this range, it is rejected as aberrant, and the
negative control mean is recalculated.
C. Positive Control Mean (in cpm) is calculated by subtracting the background
radiation from individual positive control values and taking the average of
those net values.
D. Check the validity of each run: Negative Control Mean divided by Positive
Control Mean must be greater than 5 to ensure the validity of each run.
E. Determination of Cutoff Value:
Cutoff Value = (Negative Control Mean + Positive Control Mean) / 2 +
background radiation. Samples with cpm values less than or equal to the
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cutoff value are considered reactive with respect to Anti-HBc by
criteria of the CORAB™ test.

IX. Calculation of Cutoff Value for Assay for Anti-HAV.
A. Negative Control Mean (in cpm) is calculated by subtracting background
radiation from individual negative control values and then taking the average
of those net values.
B. Positive Control Mean (in cpm) is calculated by subtracting background
radiation from individual positive control values and then taking the average
of those net values.
C. Ensuring the validity of each run: Negative Control Mean divided by
Positive Control Mean must be greater than 5 to ensure the validity of each
run.
D. Cutoff Value = (Negative Control Mean + Positive Control Mean)/2 +
background. Samples with cpm values which are less than or equal to the
cutoff value are considered reactive with respect to Anti-HAV.

X. Calculation of Cutoff Value for Anti-HAV (IgM)
A. Negative Control Mean (in cpm) is calculated by subtracting background
radiation from individual negative control values and then taking the average
of those net values.
B. Positive Control Mean (in cpm) is calculated by subtracting background
radiation from individual positive control values and then taking the avaerage
of those net values.
C. Elimination of aberrant values: Individual Positive Control values should lie
within the range of (0.5-1.5) times the Mean Positive Control value.
1. If one positive control sample lies outside this range, it is
rejected as aberrant and a revised mean positive control
value is calculated.
2. If more than one value is consistently outside the range,
technique problems should be investigated.
D. Ensuring the validity of each run: Positive Control Mean divided by
Negative Control Mean must be greater than 5.0 to ensure the validity of
each run.
E. Cutoff Value = (Positive Control Mean)/10 + Negative Control Mean +
background.
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1. Specimens with cpm values less than the cutoff value are
non-reactive by criteria of the test.
2. Specimens with cpm values repeatably greater than or
equal to the cutoff value are positive by criteria of the test
3. Specimens within +10% of the cutoff value should be
retested to confirm initial results.
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